Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
R1 RCM Inc Market Cap
The R1 RCM Inc (RCM) share price is expected to increase by 50.05% over the next year. This is based on calculating the average 12-month share price estimate provided by 13 stock analysts who have covered RCM. Price targets range from $11.00 at the low end to $20.00 at the high end. The current analyst consensus for RCM is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
R1 RCM Inc has a total of 13 Wall St Analyst ratings. There are 12 buy ratings, 1 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that R1 RCM Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| glen santangelo Jefferies | Buy | $18.0 | maintained | Feb 1, 2024 |
| charles rhyee TD Cowen | Buy | $20.0 | rated | Jan 18, 2024 |
| craig hettenbach Morgan Stanley | Buy | $17.0 | maintained | Jan 17, 2024 |
| vikram kesavabhotla Robert W. Baird | Buy | $18.0 | maintained | Jan 8, 2024 |
| richard close Canaccord Genuity | Buy | $17.0 | maintained | Jan 8, 2024 |
| sean dodge RBC Capital | Buy | $19.0 | maintained | Jan 5, 2024 |
| scott schoenhaus KeyBanc | Buy | $13.0 | maintained | Jan 5, 2024 |
| jailendra singh Truist Financial | Buy | $16.0 | maintained | Jan 4, 2024 |
| stephanie davis Barclays | Buy | $14.0 | initiatedcoverage | Jan 2, 2024 |
| daniel grosslight Citi | Buy | $14.0 | maintained | Dec 14, 2023 |
| anne samuel J.P. Morgan | Hold | $11.0 | downgraded | Dec 13, 2023 |
| george hill Deutsche Bank | Buy | $16.0 | maintained | Dec 7, 2023 |
| allen lutz Bank of America Securities | Buy | $19.0 | maintained | Dec 6, 2023 |
| jeffrey garro Stephens | Buy | $22.0 | maintained | Oct 16, 2023 |
| elizabeth anderson cfa Evercore ISI | Buy | $20.0 | maintained | Oct 11, 2023 |
| sarah james Cantor Fitzgerald | Buy | $20.0 | initiatedcoverage | Aug 15, 2023 |
| michael cherny Bank of America Securities | Buy | $23.5 | reiterated | Aug 2, 2023 |
| jack wallace Guggenheim | Buy | $21.0 | maintained | Feb 17, 2023 |
| eugene mannheimer Colliers Securities | Buy | $33.0 | reiterated | May 5, 2021 |
| steven halper Cantor Fitzgerald | Buy | $35.0 | maintained | Feb 18, 2021 |
R1 RCM Inc. provides technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and physician groups. It offers end-to-end revenue cycle management (RCM) services, which address the spectrum of revenue cycle challenges faced by healthcare providers. The company provides modular services, including physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. R1 RCM Inc. was founded in 2003 and is headquartered in Murray, Utah.
When did it IPO
0
Staff Count
27,200
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Mr. Lee Rivas
Market Cap
$4.56B
In 2023, RCM generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that RCM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
FELE-USD
$98.07
MMSI-USD
$79.45
$233.13
HCP-USD
$22.69
$34.55
COOP-USD
$72.4
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
